127 related articles for article (PubMed ID: 30234515)
1. Metabolic Acidosis in Postsurgical Patient on Canagliflozin and Metformin: A Case Report.
Darwish AM
A A Pract; 2019 Apr; 12(7):221-222. PubMed ID: 30234515
[TBL] [Abstract][Full Text] [Related]
2. Euglycemic Ketoacidosis Caused by Sodium-Glucose Cotransporter 2 Inhibitors: A Case Report.
Bobart SA; Gleason B; Martinez N; Norris K; Williams SF
Ann Intern Med; 2016 Oct; 165(7):530-532. PubMed ID: 27699391
[No Abstract] [Full Text] [Related]
3. ‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
Danford C; Chan P; Magill SB
WMJ; 2016 Aug; 115(4):206-9. PubMed ID: 29099159
[TBL] [Abstract][Full Text] [Related]
4. Combined metformin-associated lactic acidosis and euglycemic ketoacidosis.
Schwetz V; Eisner F; Schilcher G; Eller K; Plank J; Lind A; Pieber TR; Mader JK; Eller P
Wien Klin Wochenschr; 2017 Sep; 129(17-18):646-649. PubMed ID: 28865058
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes.
Donnan K; Segar L
Eur J Pharmacol; 2019 Mar; 846():23-29. PubMed ID: 30639796
[TBL] [Abstract][Full Text] [Related]
6. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin.
van Niekerk C; Wallace J; Takata M; Yu R
BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30131409
[TBL] [Abstract][Full Text] [Related]
7. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
Davidson JA; Sloan L
Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055
[TBL] [Abstract][Full Text] [Related]
8. [Severe diabetic ketoacidosis, acute kidney injury and dehydration due to canagliflozin in type 2 diabetes mellitus patient: Atypical clinical presentation].
Moreno Obregón F; Espino Montoro A; Marín Martín J; León Jiménez D
Aten Primaria; 2019 Dec; 51(10):664-666. PubMed ID: 31326123
[No Abstract] [Full Text] [Related]
9. In brief: ketoacidosis with SGLT2 inhibitors.
Med Lett Drugs Ther; 2015 Jun; 57(1471):94. PubMed ID: 26079766
[No Abstract] [Full Text] [Related]
10. Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.
Jazi M; Porfiris G
Can Fam Physician; 2016 Sep; 62(9):722-4. PubMed ID: 27629667
[No Abstract] [Full Text] [Related]
11. Quiz: Metabolic Acidosis in a Patient With Type 2 Diabetes.
Kohli J; Goldfarb S
Am J Kidney Dis; 2017 Jun; 69(6):A11-A13. PubMed ID: 28532637
[No Abstract] [Full Text] [Related]
12. Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
Adachi J; Inaba Y; Maki C
Intern Med; 2017; 56(2):187-190. PubMed ID: 28090050
[TBL] [Abstract][Full Text] [Related]
13. Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date.
Tomlinson B; Li YH
Expert Opin Pharmacother; 2023; 24(18):1937-1947. PubMed ID: 37881952
[TBL] [Abstract][Full Text] [Related]
14. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
Blau JE; Tella SH; Taylor SI; Rother KI
Diabetes Metab Res Rev; 2017 Nov; 33(8):. PubMed ID: 28736981
[TBL] [Abstract][Full Text] [Related]
15. Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor.
Koch RA; Clark RF
Am J Ther; 2018; 25(5):e590-e591. PubMed ID: 28452848
[No Abstract] [Full Text] [Related]
16. [Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. Report of one case with type 1 diabetes].
Novik A V; García B C; Oliva I D
Rev Med Chil; 2017 Mar; 145(3):393-396. PubMed ID: 28548198
[TBL] [Abstract][Full Text] [Related]
17. Euglycemic diabetic ketoacidosis with canagliflozin: Not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use.
Clement M; Senior P
Can Fam Physician; 2016 Sep; 62(9):725-8. PubMed ID: 27629668
[No Abstract] [Full Text] [Related]
18. Canagliflozin-induced Fanconi syndrome in a patient with previously unrecognized type 1 diabetes.
Khan N; Tso K; Broussard J; Dziuba M
Am J Health Syst Pharm; 2019 Nov; 76(23):1930-1933. PubMed ID: 31724039
[TBL] [Abstract][Full Text] [Related]
19. Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes.
Shamchuk A; Doulla M; Jetha M
CMAJ; 2021 Sep; 193(35):E1385-E1388. PubMed ID: 34493565
[No Abstract] [Full Text] [Related]
20. SGLT2 Inhibitors and Euglycemic Ketoacidosis.
Masuta P; Johri G; Paul M
Am J Ther; 2018; 25(4):e498-e500. PubMed ID: 28537992
[No Abstract] [Full Text] [Related]
[Next] [New Search]
